Meet our Board of Directors.

Providing expert guidance and strategic insight to help us fulfill our mission to discover, develop and commercialize life changing therapies for children and adults affected by CNS disorders and rare diseases.

Tim M. Mayleben, Lead Independent Director

Tim M. Mayleben has served on our Board since December 2008 and as Lead Independent Director since 2017. Mr. Mayleben currently serves as President, CEO and a director of Esperion Therapeutics, Inc., a pharmaceutical company that specializes in developing and commercializing non-statin, once-daily oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). Mr. Mayleben has more than a decade of executive leadership roles in the life sciences industry, including, former President, CEO and a director of Vericel Corporation (formerly Aastrom Biosciences), former President, COO and a director of Virtual Radiologics, Inc. (formerly NightHawk Radiology Holdings, Inc.), and former COO and CFO of the original Esperion, until its acquisition by Pfizer in 2004. He is also an advisor to, investor in, and member of the board of directors of several life science companies, including Kaleo, Inc. Mr. Mayleben earned an MBA, with distinction, from the J.L. Kellogg Graduate School of Management at Northwestern University, and a BBA from the University of Michigan, Ross School of Business.

icon patient resources

Explore Patient Resources

Find helpful information and patient networks, as well as clinical trial opportunities.

View Patient Resources

icon join marinus team

Join the Marinus Team

Learn how you can become part of our mission to advance mindful innovation.

Visit Careers Center